ArticleDermatology and therapy2026

Long-Term Safety and Efficacy of Tralokinumab in Patients with Moderate-to-Severe Atopic Dermatitis Treated for up to 6 Years: Final Results from the Open-Label Extension Trial ECZTEND.

Andrew Blauvelt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.